Nj State Employees Deferred Compensation Plan Xenon Pharmaceuticals Inc. Transaction History
Nj State Employees Deferred Compensation Plan
- $823 Million
- Q2 2025
A detailed history of Nj State Employees Deferred Compensation Plan transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Nj State Employees Deferred Compensation Plan holds 25,000 shares of XENE stock, worth $835,750. This represents 0.1% of its overall portfolio holdings.
Number of Shares
25,000
Previous 25,000
-0.0%
Holding current value
$835,750
Previous $838,000
6.68%
% of portfolio
0.1%
Previous 0.11%
Shares
3 transactions
Others Institutions Holding XENE
# of Institutions
224Shares Held
71.1MCall Options Held
435KPut Options Held
207K-
Avoro Capital Advisors LLC New York, NY5.74MShares$192 Million3.12% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.58MShares$153 Million1.68% of portfolio
-
Wellington Management Group LLP Boston, MA3.79MShares$127 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X03.33MShares$111 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA3.09MShares$103 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.08B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...